Logo image of SLGL

SOL-GEL TECHNOLOGIES LTD (SLGL) Stock Price, Quote, News and Overview

NASDAQ:SLGL - Nasdaq - IL0011417206 - Common Stock - Currency: USD

7.24  +0.03 (+0.42%)

SLGL Quote, Performance and Key Statistics

SOL-GEL TECHNOLOGIES LTD

NASDAQ:SLGL (6/2/2025, 8:00:02 PM)

7.24

+0.03 (+0.42%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High16.5
52 Week Low3.34
Market Cap20.20M
Shares2.79M
Float940.00K
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-14 2025-08-14
IPO02-01 2018-02-01


SLGL short term performance overview.The bars show the price performance of SLGL in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 20 30

SLGL long term performance overview.The bars show the price performance of SLGL in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SLGL is 7.24 USD. In the past month the price decreased by -0.82%. In the past year, price decreased by -11.01%.

SOL-GEL TECHNOLOGIES LTD / SLGL Daily stock chart

SLGL Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 54.3 708.08B
JNJ JOHNSON & JOHNSON 15.46 373.90B
NVO NOVO-NORDISK A/S-SPONS ADR 20.23 323.61B
NVS NOVARTIS AG-SPONSORED ADR 14.04 230.49B
AZN ASTRAZENECA PLC-SPONS ADR 16.35 223.01B
MRK MERCK & CO. INC. 9.79 191.47B
PFE PFIZER INC 7.31 133.38B
SNY SANOFI-ADR 11.05 119.71B
BMY BRISTOL-MYERS SQUIBB CO 6.65 99.29B
GSK GSK PLC-SPON ADR 9.36 84.51B
ZTS ZOETIS INC 28.14 75.43B
HLN HALEON PLC-ADR 23.29 51.37B

About SLGL

Company Profile

SLGL logo image Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. The firm is focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The Company’s offers a range of products twins, sirs-t, and vered. The firm is designed its proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Its technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin.

Company Info

SOL-GEL TECHNOLOGIES LTD

Golda Meir 7

Ness Ziona 7403648 IL

CEO: Alon Seri-Levy

Employees: 36

SLGL Company Website

SLGL Investor Relations

Phone: 97289313433

SOL-GEL TECHNOLOGIES LTD / SLGL FAQ

What is the stock price of SOL-GEL TECHNOLOGIES LTD today?

The current stock price of SLGL is 7.24 USD. The price increased by 0.42% in the last trading session.


What is the ticker symbol for SOL-GEL TECHNOLOGIES LTD stock?

The exchange symbol of SOL-GEL TECHNOLOGIES LTD is SLGL and it is listed on the Nasdaq exchange.


On which exchange is SLGL stock listed?

SLGL stock is listed on the Nasdaq exchange.


What is SOL-GEL TECHNOLOGIES LTD worth?

SOL-GEL TECHNOLOGIES LTD (SLGL) has a market capitalization of 20.20M USD. This makes SLGL a Nano Cap stock.


How many employees does SOL-GEL TECHNOLOGIES LTD have?

SOL-GEL TECHNOLOGIES LTD (SLGL) currently has 36 employees.


What are the support and resistance levels for SOL-GEL TECHNOLOGIES LTD (SLGL) stock?

SOL-GEL TECHNOLOGIES LTD (SLGL) has a support level at 7.2 and a resistance level at 7.86. Check the full technical report for a detailed analysis of SLGL support and resistance levels.


Is SOL-GEL TECHNOLOGIES LTD (SLGL) expected to grow?

The Revenue of SOL-GEL TECHNOLOGIES LTD (SLGL) is expected to decline by -42.11% in the next year. Check the estimates tab for more information on the SLGL EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SOL-GEL TECHNOLOGIES LTD (SLGL) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SOL-GEL TECHNOLOGIES LTD (SLGL) stock pay dividends?

SLGL does not pay a dividend.


When does SOL-GEL TECHNOLOGIES LTD (SLGL) report earnings?

SOL-GEL TECHNOLOGIES LTD (SLGL) will report earnings on 2025-08-14.


What is the Price/Earnings (PE) ratio of SOL-GEL TECHNOLOGIES LTD (SLGL)?

SOL-GEL TECHNOLOGIES LTD (SLGL) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.79).


SLGL Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to SLGL. When comparing the yearly performance of all stocks, SLGL is one of the better performing stocks in the market, outperforming 73.36% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SLGL Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SLGL. No worries on liquidiy or solvency for SLGL as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SLGL Financial Highlights

Over the last trailing twelve months SLGL reported a non-GAAP Earnings per Share(EPS) of -3.79. The EPS increased by 62.91% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -29.52%
ROE -36.67%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-21.3%
Sales Q2Q%-37.81%
EPS 1Y (TTM)62.91%
Revenue 1Y (TTM)644.39%

SLGL Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to SLGL. The Buy consensus is the average rating of analysts ratings from 7 analysts.

For the next year, analysts expect an EPS growth of -42.86% and a revenue growth -42.11% for SLGL


Ownership
Inst Owners18.81%
Ins Owners0.31%
Short Float %N/A
Short Ratio0.66
Analysts
Analysts82.86
Price TargetN/A
EPS Next Y-42.86%
Revenue Next Year-42.11%